Arab J Urol. 2013 Sep;11(3):237-44. doi: 10.1016/j.aju.2013.05.005. Epub 2013 Sep 12.
Stem-cell therapy for erectile dysfunction.
Arab journal of urology
Maarten Albersen, Ching-Shwun Lin, Tom Lue
Affiliations
Affiliations
- Laboratory for Experimental Urology, Gene and Stem Cells Applications, Department of Development and Regeneration, University of Leuven, Leuven, Belgium.
- Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.
PMID: 26558088
PMCID: PMC4442996 DOI: 10.1016/j.aju.2013.05.005
Abstract
INTRODUCTION: Erectile dysfunction (ED) is the most common sexual disorder that men report to healthcare providers, and is the male sexual dysfunction that has been most investigated. Current treatments for ED focus on relieving the symptoms of ED and therefore tend to provide a temporary solution rather than a cure or reversing the cause. Recently, therapies based on stem cells (SCs) have had an increasing attention for their potential to restore erectile function. Preclinical studies showed that these cells might reverse the pathophysiological changes leading to ED, rather than treating the symptoms of ED. This review is intended to provide an overview of contemporary reports on the use of SCs to treat ED.
METHODS: We made an extensive search for reports on SC-based therapy for the management of ED, published in English between 1966 and 2013, using the search engines SciVerse-sciencedirect, SciVerse-scopus, Google Scholar and Pubmed, with the search terms 'erectile dysfunction', 'stem cells', 'multipotent stromal cells', 'adipose (tissue) derived stem cells', 'bone-marrow derived stem cells', 'animal model', 'diabetes', 'ageing', 'Peyronie's Disease' and 'cavernous nerve injury'.
RESULTS: Fifty-four papers were identified and contributed, either as an original research report or review thereof, to this review. Several preclinical studies addressed SC-based therapies for the recovery of erectile function caused by a variety of both chronic and acute conditions. Overall, these studies showed beneficial effects of SC therapy, while evidence on the mechanisms of action of SC therapy varied between studies. One clinical trial investigated the short-term effects of SC therapy in diabetic patients with ED. Two more clinical trials are currently recruiting patients.
CONCLUSIONS: The rapidly expanding and highly promising body of preclinical work on SC-based medicine providing a potential cure for ED, rather than merely symptom relief, is indicative of the increasing interest in regenerative options for sexual medicine over the past decade. Clinical trials are currently recruiting patients to test the preclinical results in men with ED.
Keywords: (A)(E)(H)(M) SC, (adult) (embryonic) (haematopoietic) (mesenchymal) stem cell; (e)(n)NOS, (endothelial) (neuronal) NO synthase; AD, adipose tissue-derived; Ageing; BM, bone marrow-derived; CC, corpus cavernosum; CNI, cavernous nerve injury; Cavernous nerve injury; Diabetes; ED, erectile dysfunction; GFP, green fluorescent protein; MD, muscle-derived; MPG, major pelvic ganglion; NO, nitric oxide; PD, Peyronie’s disease; PDE5 (I), phosphodiesterase type 5 (inhibitor); Peyronie’s disease; RP, radical prostatectomy; SVF, stromal vascular fraction
References
- J Sex Med. 2011 Feb;8(2):427-36 - PubMed
- J Sex Med. 2012 Nov;9(11):2770-84 - PubMed
- BJU Int. 2008 May;101(9):1156-64 - PubMed
- Cardiol Rev. 2011 Jan-Feb;19(1):5-11 - PubMed
- BJU Int. 2004 Oct;94(6):904-9 - PubMed
- World J Stem Cells. 2011 Apr 26;3(4):25-33 - PubMed
- Eur Urol. 2007 Jan;51(1):75-88; discussion 89 - PubMed
- Int J Androl. 2012 Aug;35(4):601-7 - PubMed
- J Sex Med. 2012 Aug;9(8):1968-79 - PubMed
- Eur Urol. 2013 Mar;63(3):551-60 - PubMed
- Stem Cells. 2011 May;29(5):749-54 - PubMed
- Nat Rev Urol. 2012 Sep;9(9):520-36 - PubMed
- Tissue Eng Part A. 2013 Jan;19(1-2):14-23 - PubMed
- Adv Urol. 2008;:594868 - PubMed
- Cell Mol Neurobiol. 2013 Mar;33(2):233-40 - PubMed
- Surgery. 2008 May;143(5):577-81 - PubMed
- JAMA. 1993 Jul 7;270(1):83-90 - PubMed
- Int J Impot Res. 1996 Jun;8(2):47-52 - PubMed
- J Sex Med. 2010 Jan;7(1 Pt 1):89-98 - PubMed
- Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1278-90 - PubMed
- Eur Urol. 2013 Mar;63(3):561-2 - PubMed
- Mol Ther. 2009 Jul;17(7):1250-6 - PubMed
- J Sex Med. 2010 Apr;7(4 Pt 1):1391-400 - PubMed
- Prostate. 2013 Feb 15;73(3):278-86 - PubMed
- Cytotherapy. 2006;8(4):315-7 - PubMed
- Expert Opin Emerg Drugs. 2010 Sep;15(3):467-80 - PubMed
- J Sex Med. 2012 Feb;9(2):482-93 - PubMed
- Int Braz J Urol. 2012 Nov-Dec;38(6):833-41 - PubMed
- Curr Stem Cell Res Ther. 2010 Jun;5(2):103-10 - PubMed
- Eur Urol. 2012 Oct;62(4):720-7 - PubMed
- Gene Ther. 2002 May;9(10):642-7 - PubMed
- Exp Clin Transplant. 2010 Jun;8(2):150-60 - PubMed
- J Sex Med. 2012 Dec;9(12):3051-65 - PubMed
- Regen Med. 2010 Jan;5(1):121-43 - PubMed
- Eur Urol. 2009 Oct;56(4):716-25 - PubMed
- J Urol. 2011 Mar;185(3):1158-9; author reply 1159-61 - PubMed
- J Sex Med. 2010 Oct;7(10):3331-40 - PubMed
- Int J Impot Res. 2011 Nov-Dec;23(6):268-75 - PubMed
- J Sex Med. 2013 Jan;10(1):195-203 - PubMed
- J Sex Med. 2012 Jul;9(7):1834-41 - PubMed
- Int J Impot Res. 2006 Jul-Aug;18(4):329-34 - PubMed
- J Urol. 1998 May;159(5):1541-7 - PubMed
- Urology. 2013 Jan;81(1):104-10 - PubMed
- Asian J Androl. 2012 Jan;14(1):145-55 - PubMed
- J Androl. 2012 Jan-Feb;33(1):37-44 - PubMed
- J Urol. 2010 Oct;184(4):1560-6 - PubMed
- Andrologia. 2010 Jun;42(3):187-92 - PubMed
- J Sex Med. 2010 Jan;7(1 Pt 2):445-75 - PubMed
- J Sex Med. 2013 May;10 (5):1268-77 - PubMed
- J Sex Med. 2011 Feb;8(2):437-46 - PubMed
- Korean J Urol. 2011 May;52(5):359-63 - PubMed
- Eur Urol. 2012 Jan;61(1):201-10 - PubMed
- J Sex Med. 2012 Feb;9(2):385-403 - PubMed
Publication Types